OBJECTIVES: To compare the performance of prostate-specific antigen (PSA), the free/total PSA (F/T PSA) ratio, and complexed PSA (cPSA) in prostate cancer detection. METHODS: Five hundred thirty-five patients evaluated at the UROMED prostate cancer detection clinic had total PSA, free PSA, and cPSA measured before undergoing transrectal ultrasonography and sextant prostate biopsies. A direct comparison was performed between the different PSA assays to evaluate their ability to detect prostate cancer. RESULTS: Of the 535 patients evaluated, 38.1% had prostate cancer detected. The mean age of the entire population was 63.6 years (range 35 to 86). Abnormal digital rectal examination findings were present in 33.4% of the patients. The mean and median values of PSA and cPSA were significantly higher and the F/T PSA ratio was lower in patients with prostate cancer. The F/T PSA ratio performed better than either cPSA or total PSA. A higher specificity was observed with the F/T PSA ratio than with cPSA using either the entire patient population or subsets of patients with PSA levels between 4.0 and 10 ng/mL or 4.0 to 6.0 ng/mL. CONCLUSIONS: The use of the F/T PSA ratio offers improved prostate cancer detection compared with either cPSA or total PSA.
OBJECTIVES: To compare the performance of prostate-specific antigen (PSA), the free/total PSA (F/T PSA) ratio, and complexed PSA (cPSA) in prostate cancer detection. METHODS: Five hundred thirty-five patients evaluated at the UROMED prostate cancer detection clinic had total PSA, free PSA, and cPSA measured before undergoing transrectal ultrasonography and sextant prostate biopsies. A direct comparison was performed between the different PSA assays to evaluate their ability to detect prostate cancer. RESULTS: Of the 535 patients evaluated, 38.1% had prostate cancer detected. The mean age of the entire population was 63.6 years (range 35 to 86). Abnormal digital rectal examination findings were present in 33.4% of the patients. The mean and median values of PSA and cPSA were significantly higher and the F/T PSA ratio was lower in patients with prostate cancer. The F/T PSA ratio performed better than either cPSA or total PSA. A higher specificity was observed with the F/T PSA ratio than with cPSA using either the entire patient population or subsets of patients with PSA levels between 4.0 and 10 ng/mL or 4.0 to 6.0 ng/mL. CONCLUSIONS: The use of the F/T PSA ratio offers improved prostate cancer detection compared with either cPSA or total PSA.
Authors: Nada H Khattar; Sarah P Coe-Atkinson; Arnold J Stromberg; James R Jett; Edward A Hirschowitz Journal: Cancer Biol Ther Date: 2010-08-18 Impact factor: 4.742
Authors: F Strittmatter; P Stieber; D Nagel; C Füllhase; S Walther; C G Stief; R Waidelich Journal: Eur J Med Res Date: 2011-10-10 Impact factor: 2.175
Authors: Pierre I Karakiewicz; Serge Benayoun; Michael W Kattan; Paul Perrotte; Luc Valiquette; Peter T Scardino; Ilias Cagiannos; Hans Heinzer; Simon Tanguay; Armen G Aprikian; Hartwig Huland; Markus Graefen Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Moamen Amin; Suganthiny Jeyaganth; Nader Fahmy; Louis R Bégin; Samuel Aronson; Stephen Jacobson; Simon Tanguay; Wassim Kassouf; Armen Aprikian Journal: Can Urol Assoc J Date: 2008-10 Impact factor: 1.862
Authors: Moamen M Amin; Suganthiny Jeyaganth; Nader Fahmy; Louis Bégin; Samuel Aronson; Stephen Jacobson; Simon Tanguay; Armen G Aprikian Journal: Can Urol Assoc J Date: 2007-09 Impact factor: 1.862
Authors: Rachel A Levin; Maria E Lund; Quach Truong; Angela Wu; Neal D Shore; Daniel R Saltzstein; Raoul S Concepcion; Thomas A Paivanas; Arletta van Breda; Jennifer Beebe-Dimmer; Julie J Ruterbusch; Sandra Wissmueller; Douglas H Campbell; Bradley J Walsh Journal: Oncotarget Date: 2018-04-27